Trump Unveils New Partnerships with Drugmakers to Reduce Costs and Enhance US Investment

President Donald Trump announced on Friday that his administration has secured new agreements with some of the world’s largest drug manufacturers, aimed at reducing prescription drug costs for Americans.

During a press briefing in the Roosevelt Room, Trump revealed that nine additional drug manufacturers have joined the administration’s most-favored-nation pricing initiative. This brings the total to 14 out of the 17 largest pharmaceutical companies globally.

The agreements with these nine companies also include a substantial commitment of $150 billion towards domestic manufacturing, as well as research and development in the pharmaceutical sector.

Among the companies involved in this initiative are Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. This collaboration signifies a successful negotiation between the manufacturers and the Trump administration.

FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTS

U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC.  (Win McNamee/Getty Images / Getty Images)

Back in July, Trump sent letters to the leaders of the 17 largest drug manufacturers, seeking to negotiate a deal that would keep drug costs for those enrolled in the government’s Medicaid health program lower than those in other high-income countries.

Several of the companies that signed the recent agreements have also committed to donating active pharmaceutical ingredients to America’s Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This initiative aims to bolster the country’s disaster response capabilities in the event of pandemics, natural disasters, or national security emergencies.

Previously, companies like Pfizer, AstraZeneca, Serrano, Novo Nordisk, and Lilly had also entered into agreements with the Trump administration to maintain manageable drug prices for low-income Americans.

TRUMP’S QUEST TO REDUCE DRUG PRICES IS HEATING UP. BUT WILL HE BE ABLE TO DO IT?

The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019.  (REUTERS/Arnd Wiegmann/File Photo / Reuters)

Trump has consistently highlighted the issue of prescription drug costs as a cornerstone of his administration’s agenda. He often emphasizes the significant price disparities between the U.S. and other affluent nations. Analysts have noted that Medicaid, which accounts for 10% of the country’s drug spending, already benefits from considerable discounts provided by manufacturers, according to Reuters.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Additionally, Trump announced the upcoming launch of a new website, TrumpRX.gov, which is set to debut early next year. This initiative aims to further reduce prescription drug prices for Americans, with a message currently displayed on the site stating, “Coming soon. January 2026.”

President Donald Trump announced on Friday that his administration has secured new agreements with some of the world’s largest drug manufacturers, aimed at reducing prescription drug costs for Americans.

During a press briefing in the Roosevelt Room, Trump revealed that nine additional drug manufacturers have joined the administration’s most-favored-nation pricing initiative. This brings the total to 14 out of the 17 largest pharmaceutical companies globally.

The agreements with these nine companies also include a substantial commitment of $150 billion towards domestic manufacturing, as well as research and development in the pharmaceutical sector.

Among the companies involved in this initiative are Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. This collaboration signifies a successful negotiation between the manufacturers and the Trump administration.

FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTS

U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC.  (Win McNamee/Getty Images / Getty Images)

Back in July, Trump sent letters to the leaders of the 17 largest drug manufacturers, seeking to negotiate a deal that would keep drug costs for those enrolled in the government’s Medicaid health program lower than those in other high-income countries.

Several of the companies that signed the recent agreements have also committed to donating active pharmaceutical ingredients to America’s Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This initiative aims to bolster the country’s disaster response capabilities in the event of pandemics, natural disasters, or national security emergencies.

Previously, companies like Pfizer, AstraZeneca, Serrano, Novo Nordisk, and Lilly had also entered into agreements with the Trump administration to maintain manageable drug prices for low-income Americans.

TRUMP’S QUEST TO REDUCE DRUG PRICES IS HEATING UP. BUT WILL HE BE ABLE TO DO IT?

The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019.  (REUTERS/Arnd Wiegmann/File Photo / Reuters)

Trump has consistently highlighted the issue of prescription drug costs as a cornerstone of his administration’s agenda. He often emphasizes the significant price disparities between the U.S. and other affluent nations. Analysts have noted that Medicaid, which accounts for 10% of the country’s drug spending, already benefits from considerable discounts provided by manufacturers, according to Reuters.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Additionally, Trump announced the upcoming launch of a new website, TrumpRX.gov, which is set to debut early next year. This initiative aims to further reduce prescription drug prices for Americans, with a message currently displayed on the site stating, “Coming soon. January 2026.”